Prospective Grant of Exclusive License: Biomedical Uses of CPX (8-Cyclopentyl-1,3-Dipropylxanthine) and Related Compounds for Cystic Fibrosis and Other Human Diseases

Samenvatting

This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a worldwide, limited field of use, exclusive license to practice the inventions embodied in the patents and patent applications referred to below to SciClone Pharmaceuticals, Inc. of San Mateo, California. The patent rights in these inventions have been assigned to the government of the United States of America. The patents and patent applications to be licensed are: ``Method of Treating Cystic Fibrosis Using 8- Cyclopentyl-1,3-Dipropylxanthine or Xanthine Amino Congeners,'' U.S. Patent Application Serial No. 07/952,965 filed 29 Sep 92 (U.S. Patent No. 5,366,977 issued 22 Nov 94); ``A Method of Identifying CFTR-Binding Compounds Useful for Activating Chloride Conductance in Animal Cells,'' U.S. Patent Application Serial No. 08/343,714 filed 22 Nov 94; and all continuations, divisionals, continuations-in-part, and foreign counterparts of these two patent applications. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 an